SCHEMBL21986713

SCHEMBL21986713

COC(=O)c1c(Cl)ccc2nnn(C3CCCCO3)c12

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SLC6A3 Q01959 4/20 0.38
▸ HPGD P15428 3/20 0.34
▸ NPC1 O15118 1/20 0.34
▸ RAB9A P51151 1/20 0.34
▸ ALDH1A1 P00352 3/20 0.34
▸ ATR Q13535 1/20 0.34
▸ KDM4E B2RXH2 2/20 0.33
▸ SMN1; SMN2 Q16637 2/20 0.33
▸ TAS1R3 Q7RTX0 1/20 0.33
▸ TAS1R1 Q7RTX1 1/20 0.33
▸ TAS1R2 Q8TE23 1/20 0.33
▸ RXRA P19793 1/20 0.33
▸ RXRB P28702 1/20 0.33
▸ RXRG P48443 1/20 0.33
▸ CYP4F2 P78329 1/20 0.33
▸ CYP4A11 Q02928 1/20 0.33
▸ P2RX7 Q99572 1/20 0.33
▸ KMT2A Q03164 1/20 0.33
▸ POLB P06746 1/20 0.33
▸ HCAR3 P49019 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21986911 0.88 CYP4F2 (0.38) HPGDNPC1RAB9AALDH1A1ATR
SCHEMBL21986848 0.87 ALDH1A1 (0.39) HPGDNPC1RAB9AALDH1A1ATR
SCHEMBL21986898 0.83 SLC6A3 (0.39) SLC6A3HPGDNPC1RAB9AATR
SCHEMBL21986808 0.79 SLC6A3 (0.39) SLC6A3HPGDNPC1RAB9AALDH1A1
SCHEMBL21986732 0.72 CYP4F2 (0.38) SLC6A3HPGDNPC1RAB9AALDH1A1
SCHEMBL21986706 0.72 ALDH1A1 (0.35) HPGDNPC1RAB9AALDH1A1ATR
SCHEMBL21986760 0.72 MAPT (0.38) HPGDALDH1A1ATRKDM4ESMN1; SMN2
SCHEMBL21986866 0.70 CYP4F2 (0.37) NPC1RAB9AALDH1A1ATRKDM4E
SCHEMBL21986748 0.70 CYP4F2 (0.39) NPC1RAB9AALDH1A1ATRKDM4E
SCHEMBL21986838 0.70 ALDH1A1 (0.35) HPGDALDH1A1ATRCYP4F2CYP4A11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3660003-B1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICALS CO (JP) 2024-01-24 — — EP disclosed
US-11713311-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2023-08-01 — — US disclosed
US-20220388995-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2022-12-08 — — US disclosed
US-11230541-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2022-01-25 — — US disclosed
US-20200231579-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2020-07-23 — — US disclosed
EP-3660003-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2020-06-03 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11230541-B2 Heterocyclic compound GRIN1, GRIN2A, GRIN2B SLC6A3 721/4885HPGD 443/4885NPC1 2266/4885
US-20200231579-A1 HETEROCYCLIC COMPOUND GRIN1, GRIN2A, GRIN2B SLC6A3 721/4885HPGD 443/4885NPC1 2266/4885
US-11713311-B2 Heterocyclic compound GRIN1, GRIN2A, GRIN2B SLC6A3 721/4885HPGD 443/4885NPC1 2266/4885
US-20220388995-A1 HETEROCYCLIC COMPOUND GRIN1, GRIN2A, GRIN2B SLC6A3 721/4885HPGD 443/4885NPC1 2266/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback